Best Molecular Assay for Ovarian Clear Cell Carcinoma
DNA mismatch repair (MMR) immunohistochemistry and/or microsatellite instability (MSI) testing is the recommended molecular assay for ovarian clear cell carcinoma (CCC). 1
Primary Recommendation
The 2024 ESGO-ESMO-ESP consensus guidelines provide the strongest evidence with 100% consensus that DNA MMR IHC and/or MSI testing is recommended in ovarian clear cell carcinoma 1. This testing serves a critical therapeutic purpose: identifying patients eligible for pembrolizumab (immune checkpoint inhibitor) therapy in the recurrent setting, as this agent has tissue-agnostic FDA approval for MSI-High/dMMR tumors 2.
Clinical Context and Rationale
Clear cell carcinoma shows meaningful rates of mismatch repair deficiency:
- 11.5% of clear cell ovarian cancers exhibit dMMR 2
- These tumors are immunogenic and may respond to immune checkpoint blockade 2
- The 2020 ASCO guidelines specifically recommend that women diagnosed with clear cell, endometrioid, or mucinous ovarian cancer should be offered somatic tumor testing for dMMR 2
Testing Methodology
Multiple laboratory approaches are acceptable:
- Immunohistochemistry (IHC) for MMR protein expression (MLH1, MSH2, MSH6, PMS2) - simple, cost-effective, widely available
- PCR-based microsatellite instability testing
- Next-generation sequencing (NGS) can also assess microsatellite status 2
Important caveat: Standard MSI PCR panels may have decreased sensitivity for detecting dMMR cancers outside the GI tract. IHC is preferred for its simplicity and availability, though it may occasionally miss dMMR tumors with mutations that retain antigenicity 2.
Additional Molecular Testing Considerations
While not the primary recommendation, recent research reveals additional molecular features in clear cell carcinoma that may inform future targeted therapies:
- ARID1A mutations (most common, 49-51% of cases) 3, 4, 5
- PIK3CA mutations (47-48% of cases) 3, 4, 5
- ERBB2 (HER2) amplification/overexpression - emerging as a therapeutic target with HER2-ADCs showing efficacy 3
- Gene fusions (13% of cases, particularly MET fusions) 5
However, the 2024 guidelines explicitly state that molecular markers are not recommended for prognostication in ovarian CCC (90.2% consensus) 1, and TCGA-based molecular classification has not shown prognostic significance in clear cell carcinoma 4.
Practical Implementation
Test at diagnosis with MMR IHC and/or MSI testing to:
- Identify Lynch syndrome-related cases (hereditary cancer risk assessment)
- Establish eligibility for pembrolizumab if recurrence occurs
- Provide prognostic information (MSI-High/POLEmut cases have better relapse-free survival) 5
The testing should be performed in conjunction with germline genetic evaluation, as identification of dMMR phenotype has implications for both the patient and family members 2.